Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1448611

Rib-X Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010

Description:
Rib-X Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Rib-X Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Rib-X Pharmaceuticals, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Rib-X Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Rib-X Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Rib-X Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Rib-X Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Rib-X Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Rib-X Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Rib-X Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Rib-X Pharmaceuticals, Inc. and identify potential opportunities in those areas.
 
Contents:


List of Tables
List of Figures
Rib-X Pharmaceuticals, Inc. Snapshot
Rib-X Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Rib-X Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Rib-X Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Rib-X Pharmaceuticals, Inc. – Pipeline Products Glance
Rib-X Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Rib-X Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Rib-X Pharmaceuticals, Inc. – Drug Profiles
Delafloxacin
Product Description
Mechanism of Action
R&D Progress
RX-1741
Product Description
Mechanism of Action
R&D Progress
Rx-02
Product Description
Mechanism of Action
R&D Progress
Rx-04
Product Description
Mechanism of Action
R&D Progress
Rib-X Pharmaceuticals, Inc. – Pipeline Analysis
Rib-X Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Rib-X Pharmaceuticals, Inc. Pipeline Products By Target
Rib-X Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Rib-X Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Rib-X Pharmaceuticals, Inc. – Recent Pipeline Updates
Rib-X Pharmaceuticals, Inc. – Company Statement
Rib-X Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Sep 13, 2010: Rib-X Presents Positive Preclinical Data For Delafloxacin At ICAAC
Sep 13, 2010: Rib-X Presents Positive Preclinical Data For Delafloxacin At ICAAC
Sep 13, 2010: Rib-X Presents Positive Preclinical Data For Delafloxacin At ICAAC
Sep 13, 2010: Rib-X Presents Positive Preclinical Data For Delafloxacin At ICAAC
Sep 13, 2010: Rib-X Presents Data Supporting Delafloxacin As Potential Fluoroquinolone At ICAAC 2010 Meeting
Sep 12, 2010: Rib-X Presents Positive Pre-Clinical Data On Radezolid At 50th Interscience Conference on Antimicrobial Agents and Chemotherapy Conference
Sep 12, 2010: Rib-X Presents Positive Pre-Clinical Data On Radezolid At 50th Interscience Conference on Antimicrobial Agents and Chemotherapy Conference
Sep 12, 2010: Rib-X Presents Positive Pre-Clinical Data On Radezolid At 50th Interscience Conference on Antimicrobial Agents and Chemotherapy Conference
Dec 15, 2009: Rib-X Signs Collaborative Agreement On Delafloxacin With Massachusetts General Hospital
Dec 15, 2009: Rib-X Signs Collaborative Agreement On Delafloxacin With Massachusetts General Hospital
Financial Deals Landscape
Rib-X Pharmaceuticals, Inc., Deals Volume Summary, 2004 to YTD 2010
Rib-X Pharmaceuticals, Inc., Deals Summary By Region, 2004 to YTD 2010
Rib-X Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2010
Rib-X Pharmaceuticals, Inc. Detailed Deal Summary
Venture Financing
Rib-X Pharmaceuticals Secures $25 Million In Series D Financing
Rib-X Pharmaceuticals Raises $50 Million In Series C Financing
Rib-X Pharmaceuticals Enters Into Research Agreement With Massachusetts General Hospital
Rib-X Pharmaceuticals Enters Into An Agreement With NIAID
Evotec Enters Into Co-Development Agreement With Rib-X Pharmaceuticals
Licensing Agreements
Rib-X Pharmaceuticals Expands Licensing Agreement With Yale University
Rib-X Pharmaceuticals Enters Into Licensing Agreement With Wakunaga Pharmaceutical
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
 
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1448611

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Page 1 of 2
Printed Oct 1st 2014
8:29:39 AM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Rib-X Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010

Web Address

http://www.researchandmarkets.com/reports/1448611

Office Code

OCGOOGLE

 

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User USD 500
Electronic (PDF) - Site License USD 1,000
Electronic (PDF) - Enterprisewide USD 1,500

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Oct 1st 2014
8:29:39 AM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
 
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
 

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)